Open Access: View PDF

DOI: DOI: http://dx.doi.org/10.21088/ijog.2321.1636.6618.4

Abstract

  Background: Polycystic ovary syndrome (PCOS) is thought to be one of the most common endocrinopathies in women. It is possible to hypothesize that metformin therapy would augment the induction of ovulation in CC – resistant women because of its favourable change in adrogens, gonadotrpins, and insulin through mechanisms distinct from those of CC. Hence, the present study was undertaken to study effects of Metformin on clinical and endocrine profile in PCOS patients. Method: A total of 35 patients coming to out patient department diagnosed as a case of PCOS on the basis of common complaint of irregular menstrual cycles in whom ultrasound finding of polycystic ovaries was confirmed. All patients will receive metromin per oral 1 gm per day after breakfast for 6 mths, baseline and at six month follow up clinical examinations and endocrine profile recorded and studied. Result: Hirsutism was a compliant only in the subjects of the study with 31.4% of subjects having demonstrable levels with varied gradation. The prevalence of acne in this subject group was 20.6%. There is significant improvement in menstrual cycles regularity, p =0.00016. There is no change in acne & hirsutism complaints. Metformin is not the drug of choice for hirsutism & acne treatment. Conclusion:  Metformin was effective in restoring regular menses, metformin should be considered the first choice drug for treating oligomenorrhea in PCOS   patients in whom OCs are contraindicated. LH levels improved after metformin treatment with beneficial effect on LH: FSH
ratio and testosterone shows improved levels without change in DHEAS levels. 

Keywords: Meformin; PCOS; Hirsutism; Menstrual Cycles.  

Corresponding Author : Firdaus A. Sayyed, Senior Resident, Dept. of Obstetrics and Gynaecology, Ashwini Rural Medical College Hospital and Research Centre, Kumbhari, Maharashtra 413006, India.